Janus Henderson Group PLC Has $165.49 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Janus Henderson Group PLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 468,996 shares of the biotechnology company's stock after buying an additional 8,577 shares during the quarter. Janus Henderson Group PLC owned about 1.05% of United Therapeutics worth $165,490,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics in the fourth quarter valued at approximately $25,000. Dunhill Financial LLC lifted its stake in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB lifted its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after buying an additional 58 shares in the last quarter. Finally, Natixis bought a new position in United Therapeutics in the fourth quarter valued at approximately $85,000. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $10,437,712.18. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,500 shares of company stock worth $20,765,280. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Performance

UTHR traded up $4.24 during trading on Thursday, reaching $303.92. 486,726 shares of the stock were exchanged, compared to its average volume of 442,352. The stock has a market cap of $13.71 billion, a P/E ratio of 13.35, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a twelve month low of $264.33 and a twelve month high of $417.82. The stock's 50 day moving average price is $299.93 and its two-hundred day moving average price is $340.91.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the company earned $6.17 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on UTHR shares. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.